Table 2.
miRNA | Expression in CSCs | Relation to Stemness | Reference |
---|---|---|---|
miR-15a | Downregulated | Targets BMI-1 | [75] |
5-FU-modified mimic promotes apoptosis, inhibits invasion and overcomes resistance in CSC 1 | |||
miR-34 | Downregulated | Targets c-Met | [74] |
Overexpression downregulates CD44 and CD133 and inhibits tumor formation in vivo | |||
Enhances sensitivity to docetaxel and gemcitabine 1 | |||
miR-135b | Upregulated | Upregulated in CD44+/CD24+/ESA+ cells | [76] |
Anti-miR-135b decreases expression of NANOG, ALDH1, SOX2 and OCT-4 in vitro and suppresses tumor growth in vivo 1 | |||
miR-195 | Downregulated | Targets DCLK1 | [77] |
miR-200a | Downregulated | Overexpression downregulates CD24, CD44, ESA, N-cadherin, ZEB1, and vimentin | [78,79] |
Upregulated after DCLK1 knockdown | |||
miR-205 | Downregulated | Overexpression downregulates OCT-3/4, NANOG, CD44, and ALDH1 | [80] |
miR-1246 | Upregulated | Upregulated in CD44+/CD24+ cells | [81] |
Overexpression increases tumor sphere-forming capability and resistance to gemcitabine |
1 These miRNAs have demonstrated therapeutic potential.